1
|
Abbott BP, Abbott R, Abbott TD, Abernathy MR, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allocca A, Altin PA, Anderson SB, Anderson WG, Arai K, Arain MA, Araya MC, Arceneaux CC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Aufmuth P, Aulbert C, Babak S, Bacon P, Bader MKM, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Barayoga JC, Barclay SE, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton MA, Bartos I, Bassiri R, Basti A, Batch JC, Baune C, Bavigadda V, Bazzan M, Behnke B, Bejger M, Belczynski C, Bell AS, Bell CJ, Berger BK, Bergman J, Bergmann G, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bodiya TP, Boer M, Bogaert G, Bogan C, Bohe A, Bojtos P, Bond C, et alAbbott BP, Abbott R, Abbott TD, Abernathy MR, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allocca A, Altin PA, Anderson SB, Anderson WG, Arai K, Arain MA, Araya MC, Arceneaux CC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Aufmuth P, Aulbert C, Babak S, Bacon P, Bader MKM, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Barayoga JC, Barclay SE, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton MA, Bartos I, Bassiri R, Basti A, Batch JC, Baune C, Bavigadda V, Bazzan M, Behnke B, Bejger M, Belczynski C, Bell AS, Bell CJ, Berger BK, Bergman J, Bergmann G, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bodiya TP, Boer M, Bogaert G, Bogan C, Bohe A, Bojtos P, Bond C, Bondu F, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brau JE, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Brooks AF, Brown DA, Brown DD, Brown NM, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister T, Calloni E, Camp JB, Cannon KC, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerboni Baiardi L, Cerretani G, Cesarini E, Chakraborty R, Chalermsongsak T, Chamberlin SJ, Chan M, Chao S, Charlton P, Chassande-Mottin E, Chen HY, Chen Y, Cheng C, Chincarini A, Chiummo A, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua S, Chung S, Ciani G, Clara F, Clark JA, Cleva F, Coccia E, Cohadon PF, Colla A, Collette CG, Cominsky L, Constancio M, Conte A, Conti L, Cook D, Corbitt TR, Cornish N, Corsi A, Cortese S, Costa CA, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Craig K, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cruise AM, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Danilishin SL, D'Antonio S, Danzmann K, Darman NS, Da Silva Costa CF, Dattilo V, Dave I, Daveloza HP, Davier M, Davies GS, Daw EJ, Day R, De S, DeBra D, Debreczeni G, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Denker T, Dent T, Dereli H, Dergachev V, DeRosa RT, De Rosa R, DeSalvo R, Dhurandhar S, Díaz MC, Di Fiore L, Di Giovanni M, Di Lieto A, Di Pace S, Di Palma I, Di Virgilio A, Dojcinoski G, Dolique V, Donovan F, Dooley KL, Doravari S, Douglas R, Downes TP, Drago M, Drever RWP, Driggers JC, Du Z, Ducrot M, Dwyer SE, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Engels W, Essick RC, Etzel T, Evans M, Evans TM, Everett R, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Fang Q, Farinon S, Farr B, Farr WM, Favata M, Fays M, Fehrmann H, Fejer MM, Feldbaum D, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Finn LS, Fiori I, Fiorucci D, Fisher RP, Flaminio R, Fletcher M, Fong H, Fournier JD, Franco S, Frasca S, Frasconi F, Frede M, Frei Z, Freise A, Frey R, Frey V, Fricke TT, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard HAG, Gair JR, Gammaitoni L, Gaonkar SG, Garufi F, Gatto A, Gaur G, Gehrels N, Gemme G, Gendre B, Genin E, Gennai A, George J, Gergely L, Germain V, Ghosh A, Ghosh A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill K, Glaefke A, Gleason JR, Goetz E, Goetz R, Gondan L, González G, Gonzalez Castro JM, Gopakumar A, Gordon NA, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Graef C, Graff PB, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Greenhalgh RJS, Groot P, Grote H, Grunewald S, Guidi GM, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Hacker JJ, Hall BR, Hall ED, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Hartman MT, Haster CJ, Haughian K, Healy J, Heefner J, Heidmann A, Heintze MC, Heinzel G, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Heurs M, Hild S, Hoak D, Hodge KA, Hofman D, Hollitt SE, Holt K, Holz DE, Hopkins P, Hosken DJ, Hough J, Houston EA, Howell EJ, Hu YM, Huang S, Huerta EA, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Idrisy A, Indik N, Ingram DR, Inta R, Isa HN, Isac JM, Isi M, Islas G, Isogai T, Iyer BR, Izumi K, Jacobson MB, Jacqmin T, Jang H, Jani K, Jaranowski P, Jawahar S, Jiménez-Forteza F, Johnson WW, Johnson-McDaniel NK, Jones DI, Jones R, Jonker RJG, Ju L, Haris K, Kalaghatgi CV, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Karki S, Kasprzack M, Katsavounidis E, Katzman W, Kaufer S, Kaur T, Kawabe K, Kawazoe F, Kéfélian F, Kehl MS, Keitel D, Kelley DB, Kells W, Kennedy R, Keppel DG, Key JS, Khalaidovski A, Khalili FY, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim J, Kim K, Kim NG, Kim N, Kim YM, King EJ, King PJ, Kinzel DL, Kissel JS, Kleybolte L, Klimenko S, Koehlenbeck SM, Kokeyama K, Koley S, Kondrashov V, Kontos A, Koranda S, Korobko M, Korth WZ, Kowalska I, Kozak DB, Kringel V, Krishnan B, Królak A, Krueger C, Kuehn G, Kumar P, Kumar R, Kuo L, Kutynia A, Kwee P, Lackey BD, Landry M, Lange J, Lantz B, Lasky PD, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lebigot EO, Lee CH, Lee HK, Lee HM, Lee K, Lenon A, Leonardi M, Leong JR, Leroy N, Letendre N, Levin Y, Levine BM, Li TGF, Libson A, Littenberg TB, Lockerbie NA, Logue J, Lombardi AL, London LT, Lord JE, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lundgren AP, Luo J, Lynch R, Ma Y, MacDonald T, Machenschalk B, MacInnis M, Macleod DM, Magaña-Sandoval F, Magee RM, Mageswaran M, Majorana E, Maksimovic I, Malvezzi V, Man N, Mandel I, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan AS, Maros E, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Marx JN, Mason K, Masserot A, Massinger TJ, Masso-Reid M, Matichard F, Matone L, Mavalvala N, Mazumder N, Mazzolo G, McCarthy R, McClelland DE, McCormick S, McGuire SC, McIntyre G, McIver J, McManus DJ, McWilliams ST, Meacher D, Meadors GD, Meidam J, Melatos A, Mendell G, Mendoza-Gandara D, Mercer RA, Merilh E, Merzougui M, Meshkov S, Messenger C, Messick C, Meyers PM, Mezzani F, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller J, Millhouse M, Minenkov Y, Ming J, Mirshekari S, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moggi A, Mohan M, Mohapatra SRP, Montani M, Moore BC, Moore CJ, Moraru D, Moreno G, Morriss SR, Mossavi K, Mours B, Mow-Lowry CM, Mueller CL, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Murphy DJ, Murray PG, Mytidis A, Nardecchia I, Naticchioni L, Nayak RK, Necula V, Nedkova K, Nelemans G, Neri M, Neunzert A, Newton G, Nguyen TT, Nielsen AB, Nissanke S, Nitz A, Nocera F, Nolting D, Normandin MEN, Nuttall LK, Oberling J, Ochsner E, O'Dell J, Oelker E, Ogin GH, Oh JJ, Oh SH, Ohme F, Oliver M, Oppermann P, Oram RJ, O'Reilly B, O'Shaughnessy R, Ott CD, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan Y, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Paris HR, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patricelli B, Patrick Z, Pearlstone BL, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perreca A, Pfeiffer HP, Phelps M, Piccinni O, Pichot M, Pickenpack M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pitkin M, Poeld JH, Poggiani R, Popolizio P, Post A, Powell J, Prasad J, Predoi V, Premachandra SS, Prestegard T, Price LR, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Qin J, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rakhmanov M, Ramet CR, Rapagnani P, Raymond V, Razzano M, Re V, Read J, Reed CM, Regimbau T, Rei L, Reid S, Reitze DH, Rew H, Reyes SD, Ricci F, Riles K, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano JD, Romano R, Romanov G, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Sachdev S, Sadecki T, Sadeghian L, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sandberg V, Sandeen B, Sanders GH, Sanders JR, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Schilling R, Schmidt J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schutz BF, Scott J, Scott SM, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Serna G, Setyawati Y, Sevigny A, Shaddock DA, Shaffer T, Shah S, Shahriar MS, Shaltev M, Shao Z, Shapiro B, Shawhan P, Sheperd A, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sigg D, Silva AD, Simakov D, Singer A, Singer LP, Singh A, Singh R, Singhal A, Sintes AM, Slagmolen BJJ, Smith JR, Smith MR, Smith ND, Smith RJE, Son EJ, Sorazu B, Sorrentino F, Souradeep T, Srivastava AK, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stephens BC, Stevenson SP, Stone R, Strain KA, Straniero N, Stratta G, Strauss NA, Strigin S, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Talukder D, Tanner DB, Tápai M, Tarabrin SP, Taracchini A, Taylor R, Theeg T, Thirugnanasambandam MP, Thomas EG, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Tomlinson C, Tonelli M, Torres CV, Torrie CI, Töyrä D, Travasso F, Traylor G, Trifirò D, Tringali MC, Trozzo L, Tse M, Turconi M, Tuyenbayev D, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Vass S, Vasúth M, Vaulin R, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Verkindt D, Vetrano F, Viceré A, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Voss D, Vousden WD, Vyatchanin SP, Wade AR, Wade LE, Wade M, Waldman SJ, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang M, Wang X, Wang Y, Ward H, Ward RL, Warner J, Was M, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Welborn T, Wen L, Weßels P, Westphal T, Wette K, Whelan JT, Whitcomb SE, White DJ, Whiting BF, Wiesner K, Wilkinson C, Willems PA, Williams L, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkelmann L, Winkler W, Wipf CC, Wiseman AG, Wittel H, Woan G, Worden J, Wright JL, Wu G, Yablon J, Yakushin I, Yam W, Yamamoto H, Yancey CC, Yap MJ, Yu H, Yvert M, Zadrożny A, Zangrando L, Zanolin M, Zendri JP, Zevin M, Zhang F, Zhang L, Zhang M, Zhang Y, Zhao C, Zhou M, Zhou Z, Zhu XJ, Zucker ME, Zuraw SE, Zweizig J. Observation of Gravitational Waves from a Binary Black Hole Merger. PHYSICAL REVIEW LETTERS 2016; 116:061102. [PMID: 26918975 DOI: 10.1103/physrevlett.116.061102] [Show More Authors] [Citation(s) in RCA: 1456] [Impact Index Per Article: 161.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Indexed: 05/04/2023]
Abstract
On September 14, 2015 at 09:50:45 UTC the two detectors of the Laser Interferometer Gravitational-Wave Observatory simultaneously observed a transient gravitational-wave signal. The signal sweeps upwards in frequency from 35 to 250 Hz with a peak gravitational-wave strain of 1.0×10(-21). It matches the waveform predicted by general relativity for the inspiral and merger of a pair of black holes and the ringdown of the resulting single black hole. The signal was observed with a matched-filter signal-to-noise ratio of 24 and a false alarm rate estimated to be less than 1 event per 203,000 years, equivalent to a significance greater than 5.1σ. The source lies at a luminosity distance of 410(-180)(+160) Mpc corresponding to a redshift z=0.09(-0.04)(+0.03). In the source frame, the initial black hole masses are 36(-4)(+5)M⊙ and 29(-4)(+4)M⊙, and the final black hole mass is 62(-4)(+4)M⊙, with 3.0(-0.5)(+0.5)M⊙c(2) radiated in gravitational waves. All uncertainties define 90% credible intervals. These observations demonstrate the existence of binary stellar-mass black hole systems. This is the first direct detection of gravitational waves and the first observation of a binary black hole merger.
Collapse
|
|
9 |
1456 |
2
|
Golding J, Pembrey M, Jones R. ALSPAC--the Avon Longitudinal Study of Parents and Children. I. Study methodology. Paediatr Perinat Epidemiol 2001; 15:74-87. [PMID: 11237119 DOI: 10.1046/j.1365-3016.2001.00325.x] [Citation(s) in RCA: 1045] [Impact Index Per Article: 43.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
ALSPAC (The Avon Longitudinal Study of Parents and Children, formerly the Avon Longitudinal Study of Pregnancy and Childhood) was specifically designed to determine ways in which the individual's genotype combines with environmental pressures to influence health and development. To date, there are comprehensive data on approximately 10,000 children and their parents, from early pregnancy until the children are aged between 8 and 9. The study aims to continue to collect detailed data on the children as they go through puberty noting, in particular, changes in anthropometry, attitudes and behaviour, fitness and other cardiovascular risk factors, bone mineralisation, allergic symptoms and mental health. The study started early during pregnancy and collected very detailed data from the mother and her partner before the child was born. This not only provided accurate data on concurrent features, especially medication, symptoms, diet and lifestyle, attitudes and behaviour, social and environmental features, but was unbiased by parental knowledge of any problems that the child might develop. From the time of the child's birth many different aspects of the child's environment have been monitored and a wide range of phenotypic data collected. By virtue of being based in one geographic area, linkage to medical and educational records is relatively simple, and hands-on assessments of children and parents using local facilities has the advantage of high quality control. The comprehensiveness of the ALSPAC approach with a total population sample unselected by disease status, and the availability of parental genotypes, provides an adequate sample for statistical analysis and for avoiding spurious results. The study has an open policy in regard to collaboration within strict confidentiality rules.
Collapse
|
|
24 |
1045 |
3
|
Abbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Afrough M, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Bader MKM, Bae S, Bailes M, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Barthelmy SD, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, et alAbbott BP, Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Afrough M, Agarwal B, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allen G, Allocca A, Altin PA, Amato A, Ananyeva A, Anderson SB, Anderson WG, Angelova SV, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Atallah DV, Aufmuth P, Aulbert C, AultONeal K, Austin C, Avila-Alvarez A, Babak S, Bacon P, Bader MKM, Bae S, Bailes M, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Banagiri S, Barayoga JC, Barclay SE, Barish BC, Barker D, Barkett K, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Barthelmy SD, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Bawaj M, Bayley JC, Bazzan M, Bécsy B, Beer C, Bejger M, Belahcene I, Bell AS, Berger BK, Bergmann G, Bernuzzi S, Bero JJ, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Billman CR, Birch J, Birney R, Birnholtz O, Biscans S, Biscoveanu S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blackman J, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Bode N, Boer M, Bogaert G, Bohe A, Bondu F, Bonilla E, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bossie K, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Branchesi M, Brau JE, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Broida JE, Brooks AF, Brown DA, Brown DD, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister TA, Calloni E, Camp JB, Canepa M, Canizares P, Cannon KC, Cao H, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Carney MF, Carullo G, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerdá-Durán P, Cerretani G, Cesarini E, Chamberlin SJ, Chan M, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee D, Chatziioannou K, Cheeseboro BD, Chen HY, Chen X, Chen Y, Cheng HP, Chia H, Chincarini A, Chiummo A, Chmiel T, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua AJK, Chua S, Chung AKW, Chung S, Ciani G, Ciolfi R, Cirelli CE, Cirone A, Clara F, Clark JA, Clearwater P, Cleva F, Cocchieri C, Coccia E, Cohadon PF, Cohen D, Colla A, Collette CG, Cominsky LR, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corley KR, Cornish N, Corsi A, Cortese S, Costa CA, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Covas PB, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Cripe J, Crowder SG, Cullen TJ, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Dálya G, Danilishin SL, D'Antonio S, Danzmann K, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davis D, Daw EJ, Day B, De S, DeBra D, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Demos N, Denker T, Dent T, De Pietri R, Dergachev V, De Rosa R, DeRosa RT, De Rossi C, DeSalvo R, de Varona O, Devenson J, Dhurandhar S, Díaz MC, Dietrich T, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Di Pace S, Di Palma I, Di Renzo F, Doctor Z, Dolique V, Donovan F, Dooley KL, Doravari S, Dorrington I, Douglas R, Dovale Álvarez M, Downes TP, Drago M, Dreissigacker C, Driggers JC, Du Z, Ducrot M, Dudi R, Dupej P, Dwyer SE, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Eisenstein RA, Essick RC, Estevez D, Etienne ZB, Etzel T, Evans M, Evans TM, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Farinon S, Farr B, Farr WM, Fauchon-Jones EJ, Favata M, Fays M, Fee C, Fehrmann H, Feicht J, Fejer MM, Fernandez-Galiana A, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Finstad D, Fiori I, Fiorucci D, Fishbach M, Fisher RP, Fitz-Axen M, Flaminio R, Fletcher M, Fong H, Font JA, Forsyth PWF, Forsyth SS, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fries EM, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard H, Gadre BU, Gaebel SM, Gair JR, Gammaitoni L, Ganija MR, Gaonkar SG, Garcia-Quiros C, Garufi F, Gateley B, Gaudio S, Gaur G, Gayathri V, Gehrels N, Gemme G, Genin E, Gennai A, George D, George J, Gergely L, Germain V, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill K, Glover L, Goetz E, Goetz R, Gomes S, Goncharov B, González G, Gonzalez Castro JM, Gopakumar A, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Gretarsson EM, Groot P, Grote H, Grunewald S, Gruning P, Guidi GM, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Halim O, Hall BR, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hannuksela OA, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Heptonstall AW, Heurs M, Hild S, Hinderer T, Ho WCG, Hoak D, Hofman D, Holt K, Holz DE, Hopkins P, Horst C, Hough J, Houston EA, Howell EJ, Hreibi A, Hu YM, Huerta EA, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Indik N, Inta R, Intini G, Isa HN, Isac JM, Isi M, Iyer BR, Izumi K, Jacqmin T, Jani K, Jaranowski P, Jawahar S, Jiménez-Forteza F, Johnson WW, Johnson-McDaniel NK, Jones DI, Jones R, Jonker RJG, Ju L, Junker J, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Kastaun W, Katolik M, Katsavounidis E, Katzman W, Kaufer S, Kawabe K, Kéfélian F, Keitel D, Kemball AJ, Kennedy R, Kent C, Key JS, Khalili FY, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim W, Kim WS, Kim YM, Kimbrell SJ, King EJ, King PJ, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knowles TD, Koch P, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Krämer C, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar P, Kumar R, Kumar S, Kuo L, Kutynia A, Kwang S, Lackey BD, Lai KH, Landry M, Lang RN, Lange J, Lantz B, Lanza RK, Larson SL, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lee CH, Lee HK, Lee HM, Lee HW, Lee K, Lehmann J, Lenon A, Leon E, Leonardi M, Leroy N, Letendre N, Levin Y, Li TGF, Linker SD, Littenberg TB, Liu J, Liu X, Lo RKL, Lockerbie NA, London LT, Lord JE, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lovelace G, Lück H, Lumaca D, Lundgren AP, Lynch R, Ma Y, Macas R, Macfoy S, Machenschalk B, MacInnis M, Macleod DM, Magaña Hernandez I, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Man N, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsh P, Martelli F, Martellini L, Martin IW, Martin RM, Martynov DV, Marx JN, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Matichard F, Matone L, Mavalvala N, Mazumder N, McCarthy R, McClelland DE, McCormick S, McCuller L, McGuire SC, McIntyre G, McIver J, McManus DJ, McNeill L, McRae T, McWilliams ST, Meacher D, Meadors GD, Mehmet M, Meidam J, Mejuto-Villa E, Melatos A, Mendell G, Mercer RA, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller BB, Miller J, Millhouse M, Milovich-Goff MC, Minazzoli O, Minenkov Y, Ming J, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moffa D, Moggi A, Mogushi K, Mohan M, Mohapatra SRP, Molina I, Montani M, Moore CJ, Moraru D, Moreno G, Morisaki S, Morriss SR, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Muratore M, Murray PG, Nagar A, Napier K, Nardecchia I, Naticchioni L, Nayak RK, Neilson J, Nelemans G, Nelson TJN, Nery M, Neunzert A, Nevin L, Newport JM, Newton G, Ng KKY, Nguyen P, Nguyen TT, Nichols D, Nielsen AB, Nissanke S, Nitz A, Noack A, Nocera F, Nolting D, North C, Nuttall LK, Oberling J, O'Dea GD, Ogin GH, Oh JJ, Oh SH, Ohme F, Okada MA, Oliver M, Oppermann P, Oram RJ, O'Reilly B, Ormiston R, Ortega LF, O'Shaughnessy R, Ossokine S, Ottaway DJ, Overmier H, Owen BJ, Pace AE, Page J, Page MA, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pan HW, Pang B, Pang PTH, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Parida A, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patil M, Patricelli B, Pearlstone BL, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perez CJ, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pirello M, Pitkin M, Poe M, Poggiani R, Popolizio P, Porter EK, Post A, Powell J, Prasad J, Pratt JWW, Pratten G, Predoi V, Prestegard T, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov LG, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rajbhandari B, Rakhmanov M, Ramirez KE, Ramos-Buades A, Rapagnani P, Raymond V, Razzano M, Read J, Regimbau T, Rei L, Reid S, Reitze DH, Ren W, Reyes SD, Ricci F, Ricker PM, Rieger S, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano JD, Romano R, Romel CL, Romie JH, Rosińska D, Ross MP, Rowan S, Rüdiger A, Ruggi P, Rutins G, Ryan K, Sachdev S, Sadecki T, Sadeghian L, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sampson LM, Sanchez EJ, Sanchez LE, Sanchis-Gual N, Sandberg V, Sanders JR, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter O, Savage RL, Sawadsky A, Schale P, Scheel M, Scheuer J, Schmidt J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schulte BW, Schutz BF, Schwalbe SG, Scott J, Scott SM, Seidel E, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Shaddock DA, Shaffer TJ, Shah AA, Shahriar MS, Shaner MB, Shao L, Shapiro B, Shawhan P, Sheperd A, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer LP, Singh A, Singhal A, Sintes AM, Slagmolen BJJ, Smith B, Smith JR, Smith RJE, Somala S, Son EJ, Sonnenberg JA, Sorazu B, Sorrentino F, Souradeep T, Spencer AP, Srivastava AK, Staats K, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stevenson SP, Stone R, Stops DJ, Strain KA, Stratta G, Strigin SE, Strunk A, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Suresh J, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Tait SC, Talbot C, Talukder D, Tanner DB, Tápai M, Taracchini A, Tasson JD, Taylor JA, Taylor R, Tewari SV, Theeg T, Thies F, Thomas EG, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tonelli M, Tornasi Z, Torres-Forné A, Torrie CI, Töyrä D, Travasso F, Traylor G, Trinastic J, Tringali MC, Trozzo L, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tuyenbayev D, Ueno K, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Varma V, Vass S, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Venugopalan G, Verkindt D, Vetrano F, Viceré A, Viets AD, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walet R, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang JZ, Wang WH, Wang YF, Ward RL, Warner J, Was M, Watchi J, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wen L, Wessel EK, Weßels P, Westerweck J, Westphal T, Wette K, Whelan JT, Whitcomb SE, Whiting BF, Whittle C, Wilken D, Williams D, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Wofford J, Wong KWK, Worden J, Wright JL, Wu DS, Wysocki DM, Xiao S, Yamamoto H, Yancey CC, Yang L, Yap MJ, Yazback M, Yu H, Yu H, Yvert M, Zadrożny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang L, Zhang M, Zhang T, Zhang YH, Zhao C, Zhou M, Zhou Z, Zhu SJ, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J. GW170817: Observation of Gravitational Waves from a Binary Neutron Star Inspiral. PHYSICAL REVIEW LETTERS 2017; 119:161101. [PMID: 29099225 DOI: 10.1103/physrevlett.119.161101] [Show More Authors] [Citation(s) in RCA: 890] [Impact Index Per Article: 111.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Indexed: 05/21/2023]
Abstract
On August 17, 2017 at 12∶41:04 UTC the Advanced LIGO and Advanced Virgo gravitational-wave detectors made their first observation of a binary neutron star inspiral. The signal, GW170817, was detected with a combined signal-to-noise ratio of 32.4 and a false-alarm-rate estimate of less than one per 8.0×10^{4} years. We infer the component masses of the binary to be between 0.86 and 2.26 M_{⊙}, in agreement with masses of known neutron stars. Restricting the component spins to the range inferred in binary neutron stars, we find the component masses to be in the range 1.17-1.60 M_{⊙}, with the total mass of the system 2.74_{-0.01}^{+0.04}M_{⊙}. The source was localized within a sky region of 28 deg^{2} (90% probability) and had a luminosity distance of 40_{-14}^{+8} Mpc, the closest and most precisely localized gravitational-wave signal yet. The association with the γ-ray burst GRB 170817A, detected by Fermi-GBM 1.7 s after the coalescence, corroborates the hypothesis of a neutron star merger and provides the first direct evidence of a link between these mergers and short γ-ray bursts. Subsequent identification of transient counterparts across the electromagnetic spectrum in the same location further supports the interpretation of this event as a neutron star merger. This unprecedented joint gravitational and electromagnetic observation provides insight into astrophysics, dense matter, gravitation, and cosmology.
Collapse
|
|
8 |
890 |
4
|
Malfertheiner P, Mégraud F, O'Morain C, Hungin APS, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16:167-80. [PMID: 11860399 DOI: 10.1046/j.1365-2036.2002.01169.x] [Citation(s) in RCA: 842] [Impact Index Per Article: 36.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Significant progress and new insights have been gained in the 4 years since the first Maastricht Consensus Report, necessitating an update of the original guidelines. To achieve this, the European Helicobacter Pylori Study Group organized a meeting of specialists and experts from around the world, representatives from National Gastroenterology Societies and general practitioners from Europe to establish updated guidelines on the current management of Helicobacter pylori infection. The meeting took place on 21-22 September 2000. A "test and treat" approach is recommended in adult patients under the age of 45 years (the age cut-off may vary locally) presenting in primary care with persistent dyspepsia, having excluded those with predominantly gastro-oesophageal reflux disease symptoms, non-steroidal anti-inflammatory drug users and those with alarm symptoms. Diagnosis of infection should be by urea breath test or stool antigen test. As in the previous guidelines, the eradication of H. pylori is strongly recommended in all patients with peptic ulcer, including those with complications, in those with low-grade gastric mucosa-associated lymphoid tissue lymphoma, in those with atrophic gastritis and following gastric cancer resection. It is also strongly recommended in patients who are first-degree relatives of gastric cancer patients and according to patients' wishes after full consultation. It is advised that H. pylori eradication is considered to be an appropriate option in infected patients with functional dyspepsia, as it leads to long-term symptom improvement in a subset of patients. There was consensus that the eradication of H. pylori is not associated with the development of gastro-oesophageal reflux disease in most cases, and does not exacerbate existing gastro-oesophageal reflux disease. It was agreed that the eradication of H. pylori prior to the use of non-steroidal anti-inflammatory drugs reduces the incidence of peptic ulcer, but does not enhance the healing of gastric or duodenal ulcer in patients receiving antisecretory therapy who continue to take non-steroidal anti-inflammatory drugs. Treatment should be thought of as a package which considers first- and second-line eradication therapies together. First-line therapy should be with triple therapy using a proton pump inhibitor or ranitidine bismuth citrate, combined with clarithromycin and amoxicillin or metronidazole. Second-line therapy should use quadruple therapy with a proton pump inhibitor, bismuth, metronidazole and tetracycline. Where bismuth is not available, second-line therapy should be with proton pump inhibitor-based triple therapy. If second-line quadruple therapy fails in primary care, patients should be referred to a specialist. Subsequent failures should be handled on a case-by-case basis by the specialist. In patients with uncomplicated duodenal ulcer, eradication therapy does not need to be followed by further antisecretory treatment. Successful eradication should always be confirmed by urea breath test or an endoscopy-based test if endoscopy is clinically indicated. Stool antigen test is the alternative if urea breath test is not available.
Collapse
|
Consensus Development Conference |
23 |
842 |
5
|
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68:1827-32. [PMID: 19054820 DOI: 10.1136/ard.2008.101279] [Citation(s) in RCA: 805] [Impact Index Per Article: 50.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Comprehensive multisystem clinical assessment using the Birmingham Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis. Extensive use suggested a need to revise the instrument. The previous version of BVAS has been revised, according to usage and reviewed by an expert committee. OBJECTIVE To modify and validate version 3 of the BVAS in patients with systemic vasculitis. METHODS The new version of BVAS was tested in a prospective cross-sectional study of patients with vasculitis. RESULTS The number of items was reduced from 66 to 56. The subscores for new/worse disease and persistent disease were unified. In 313 patients with systemic vasculitis, BVAS(v.3) correlated with treatment decision (Spearman's r(s) = 0.66, 95% CI 0.59 to 0.72), BVAS1 of version 2 (r(s) = 0.94, 95% CI 0.92 to 0.96), BVAS2 of version 2 in patients with persistent disease (r(s) = 0.60, 95% CI 0.21 to 0.83), C-reactive protein levels (r(s) = 0.43, 95% CI 0.31 to 0.54), physician's global assessment (r(s) = 0.91, 95% CI 0.89 to 0.93) and vasculitis activity index (r(s) = 0.88, 95% CI 0.86 to 0.91). The intraclass correlation coefficients for reproducibility and repeatability were 0.96 (95% CI 0.95 to 0.97) and 0.96 (95% CI 0.92 to 0.97), respectively. In 39 patients assessed at diagnosis and again at 3 months, the BVAS(v.3) fell by 17 (95% CI 15 to 19) units (p<0.001, paired t test). CONCLUSION BVAS(v.3) demonstrates convergence with BVAS(v.2), treatment decision, physician global assessment of disease activity, vasculitis activity index and C-reactive protein. It is repeatable, reproducible and sensitive to change. The new version of BVAS is validated for assessment of systemic vasculitis.
Collapse
|
Validation Study |
16 |
805 |
6
|
Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83:2038-47. [PMID: 2040056 DOI: 10.1161/01.cir.83.6.2038] [Citation(s) in RCA: 686] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Background. The gas nitric oxide (NO) is an important endothelium-derived relaxing factor, inactivated by rapid combination with heme in hemoglobin. Methods and Results. Awake spontaneously breathing lambs inhaled 5-80 ppm NO with an acutely constricted pulmonary circulation due to either infusion of the stable thromboxane endoperoxide analogue U46619 or breathing a hypoxic gas mixture. Within 3 minutes after adding 40 ppm NO or more to inspired gas, pulmonary hypertension was reversed. Systemic vasodilation did not occur. Pulmonary hypertension resumed within 3-6 minutes of ceasing NO inhalation. During U46619 infusion pulmonary vasodilation was maintained up to 1 hour without tolerance. In the normal lamb, NO inhalation produced no hemodynamic changes. Breathing 80 ppm NO for 3 hours did not increase either methemoglobin or extravascular lung water levels nor modify lung histology compared with control lambs. Conclusions. Low dose inhaled NO (5-80 ppm) is a selective pulmonary vasodilator reversing both hypoxia- and thromboxane-induced pulmonary hypertension in the awake lamb [corrected].
Collapse
|
|
34 |
686 |
7
|
Baron-Cohen S, O'Riordan M, Stone V, Jones R, Plaisted K. Recognition of faux pas by normally developing children and children with Asperger syndrome or high-functioning autism. J Autism Dev Disord 1999; 29:407-18. [PMID: 10587887 DOI: 10.1023/a:1023035012436] [Citation(s) in RCA: 666] [Impact Index Per Article: 25.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Most theory of mind (ToM) tests are designed for subjects with a mental age of 4-6 years. There are very few ToM tests for subjects who are older or more able than this. We report a new test of ToM, designed for children 7-11 years old. The task involves recognizing faux pas. Study 1 tested 7-9, and 11-year-old normal children. Results showed that the ability to detect faux pas developed with age and that there was a differential developmental profile between the two sexes (female superiority). Study 2 tested children with Asperger syndrome (AS) or high-functioning autism (HFA), selected for being able to pass traditional 4- to 6-year level (first- and second-order) false belief tests. Results showed that whereas normal 9- to 11-year-old children were skilled at detecting faux pas, children with AS or HFA were impaired on this task. Study 3 reports a refinement in the test, employing control stimuli. This replicated the results from Study 2. Some patients with AS or HFA were able to recognize faux pas but still produced them. Future research should assess faux pas production.
Collapse
|
|
26 |
666 |
8
|
Wisløff U, Castagna C, Helgerud J, Jones R, Hoff J. Strong correlation of maximal squat strength with sprint performance and vertical jump height in elite soccer players. Br J Sports Med 2005; 38:285-8. [PMID: 15155427 PMCID: PMC1724821 DOI: 10.1136/bjsm.2002.002071] [Citation(s) in RCA: 602] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND A high level of strength is inherent in elite soccer play, but the relation between maximal strength and sprint and jumping performance has not been studied thoroughly. OBJECTIVE To determine whether maximal strength correlates with sprint and vertical jump height in elite male soccer players. METHODS Seventeen international male soccer players (mean (SD) age 25.8 (2.9) years, height 177.3 (4.1) cm, weight 76.5 (7.6) kg, and maximal oxygen uptake 65.7 (4.3) ml/kg/min) were tested for maximal strength in half squats and sprinting ability (0-30 m and 10 m shuttle run sprint) and vertical jumping height. RESULT There was a strong correlation between maximal strength in half squats and sprint performance and jumping height. CONCLUSIONS Maximal strength in half squats determines sprint performance and jumping height in high level soccer players. High squat strength did not imply reduced maximal oxygen consumption. Elite soccer players should focus on maximal strength training, with emphasis on maximal mobilisation of concentric movements, which may improve their sprinting and jumping performance.
Collapse
|
Journal Article |
20 |
602 |
9
|
Abstract
Tests of clinical competence, which allow decisions to be made about medical qualification and fitness to practise, must be designed with respect to key issues including blueprinting, validity, reliability, and standard setting, as well as clarity about their formative or summative function. Multiple choice questions, essays, and oral examinations could be used to test factual recall and applied knowledge, but more sophisticated methods are needed to assess clincial performance, including directly observed long and short cases, objective structured clinical examinations, and the use of standardised patients. The goal of assessment in medical education remains the development of reliable measurements of student performance which, as well as having predictive value for subsequent clinical competence, also have a formative, educational role.
Collapse
|
Review |
24 |
563 |
10
|
Naylor M, Brooten D, Jones R, Lavizzo-Mourey R, Mezey M, Pauly M. Comprehensive discharge planning for the hospitalized elderly. A randomized clinical trial. Ann Intern Med 1994; 120:999-1006. [PMID: 8185149 DOI: 10.7326/0003-4819-120-12-199406150-00005] [Citation(s) in RCA: 557] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
OBJECTIVE To study the effects of a comprehensive discharge planning protocol, designed specifically for the elderly and implemented by nurse specialists, on patient and caregiver outcomes and cost of care. DESIGN Randomized clinical trial. SETTING Hospital of the University of Pennsylvania. PATIENTS 276 patients and 125 caregivers. Patients were 70 years and older and were placed in selected medical and surgical cardiac diagnostic-related groups. MEASUREMENTS Group differences in patient outcomes (length of initial hospital stay, length of time between initial hospital discharge and readmission, and rehospitalization rates) and charges for care (charges for initial hospitalization, rehospitalizations, health services after discharge, and nurse specialist services) were measured 2, 6, and 12 weeks after discharge. RESULTS From the initial hospital discharge to 6 weeks after discharge, patients in the medical intervention group had fewer readmissions, fewer total days rehospitalized, lower readmission charges, and lower charges for health care services after discharge. No differences in these outcomes were found between the surgical intervention and control groups during this period. CONCLUSIONS Study findings support the need for comprehensive discharge planning designed for the elderly and implemented by nurse specialists to improve their outcomes after hospital discharge and to achieve cost savings. The findings also suggest that this intervention had its greatest effect in delaying or preventing rehospitalization of patients in the medical intervention group during the first 6 weeks after discharge.
Collapse
|
Clinical Trial |
31 |
557 |
11
|
Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P, Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56:1770-98. [PMID: 17488783 PMCID: PMC2095723 DOI: 10.1136/gut.2007.119446] [Citation(s) in RCA: 538] [Impact Index Per Article: 29.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Revised: 04/20/2007] [Accepted: 05/01/2007] [Indexed: 12/14/2022]
Abstract
BACKGROUND IBS affects 5-11% of the population of most countries. Prevalence peaks in the third and fourth decades, with a female predominance. AIM To provide a guide for the assessment and management of adult patients with irritable bowel syndrome. METHODS Members of the Clinical Services Committee of The British Society of Gastroenterology were allocated particular areas to produce review documents. Literature searching included systematic searches using electronic databases such as Pubmed, EMBASE, MEDLINE, Web of Science, and Cochrane databases and extensive personal reference databases. RESULTS Patients can usefully be classified by predominant bowel habit. Few investigations are needed except when diarrhoea is a prominent feature. Alarm features may warrant further investigation. Adverse psychological features and somatisation are often present. Ascertaining the patients' concerns and explaining symptoms in simple terms improves outcome. IBS is a heterogeneous condition with a range of treatments, each of which benefits a small proportion of patients. Treatment of associated anxiety and depression often improves bowel and other symptoms. Randomised placebo controlled trials show benefit as follows: cognitive behavioural therapy and psychodynamic interpersonal therapy improve coping; hypnotherapy benefits global symptoms in otherwise refractory patients; antispasmodics and tricyclic antidepressants improve pain; ispaghula improves pain and bowel habit; 5-HT(3) antagonists improve global symptoms, diarrhoea, and pain but may rarely cause unexplained colitis; 5-HT(4) agonists improve global symptoms, constipation, and bloating; selective serotonin reuptake inhibitors improve global symptoms. CONCLUSIONS Better ways of identifying which patients will respond to specific treatments are urgently needed.
Collapse
|
Practice Guideline |
18 |
538 |
12
|
Jones R, Mann T, Sherins R. Peroxidative breakdown of phospholipids in human spermatozoa, spermicidal properties of fatty acid peroxides, and protective action of seminal plasma. Fertil Steril 1979; 31:531-7. [PMID: 446777 DOI: 10.1016/s0015-0282(16)43999-3] [Citation(s) in RCA: 483] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Aerobic incubation of human spermatozoa in the presence of catalytic amounts of ascorbate and ferrous ion results in rapid peroxidative breakdown of sperm phospholipids and fatty acids; most strongly affected are phosphatidyl ethanolamine, ethanolamine plasmalogen, and docosahexanoic acid. Both peroxidation of the endogenous sperm phospholipid and the concurrent loss of motility can be fully prevented, but not reversed, by an "antiperoxidant" factor present in human seminal plasma. Exogenously applied lipid peroxides are powerfully spermicidal. Washed human spermatozoa, at a concentration normally present in semen, treated with as little as 30 nmoles of lipid peroxide/ml become irreversibly immotile within a few minutes. The antiperoxidant factor present in human seminal plasma effectively counteracts the toxic effect of exogenous peroxidized fatty acids upon human spermatozoa, but is unable to restore motility lost by lipid peroxide action.
Collapse
|
|
46 |
483 |
13
|
Jones R, Junghard O, Dent J, Vakil N, Halling K, Wernersson B, Lind T. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009; 30:1030-8. [PMID: 19737151 DOI: 10.1111/j.1365-2036.2009.04142.x] [Citation(s) in RCA: 476] [Impact Index Per Article: 29.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Accurate diagnosis and effective management of gastro-oesophageal reflux disease (GERD) can be challenging for clinicians and other health care professionals. AIM To develop a patient-centred, self-assessment questionnaire to assist health care professionals in the diagnosis and effective management of patients with GERD. METHODS Questions from patient-reported GERD instruments, previously documented in terms of content validity and psychometric properties (RDQ, GSRS and GIS) and data on the diagnosis of GERD in primary and secondary care were used in the formal development of a diagnostic and management tool, the GerdQ, involving psychometric validation and piloting in patient focus groups. RESULTS Analyses of data from over 300 primary care patients, moderated by patient input from qualitative interviews, were used to select specific items from the existing instruments to create a new six-item diagnostic and management tool (GerdQ). ROC analysis indicated a sensitivity for GerdQ of 65% and a specificity of 71% for the diagnosis of GERD, similar to that achieved by gastroenterologists. CONCLUSION The GerdQ is a potentially useful tool for family practitioners and other health care professionals in diagnosing and managing GERD without initial specialist referral or endoscopy.
Collapse
|
|
16 |
476 |
14
|
Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000; 97:14608-13. [PMID: 11121063 PMCID: PMC18966 DOI: 10.1073/pnas.97.26.14608] [Citation(s) in RCA: 459] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2000] [Indexed: 12/13/2022] Open
Abstract
The presence of "mosaic" vessels in which both endothelial cells and tumor cells form the luminal surface has profound implications for metastasis, drug delivery, and antivascular therapy. Yet little is known of the frequency, and thus importance, of mosaic vessels in tumors. Using CD31 and CD105 to identify endothelial cells and endogenous green fluorescent protein labeling of tumor cells, we show that approximately 15% of perfused vessels of a colon carcinoma xenografted at two different sites in mice were mosaic vessels having focal regions where no CD31/CD105 immunoreactivity was detected and tumor cells appeared to contact the vessel lumen. These regions occupied approximately 25% of the perimeter of the mosaic vessels, or approximately 4% of the total vascular surface area in these colon carcinomas. In addition, we found similar numbers of mosaic vessels in human colon carcinoma biopsies. Our results are consistent with the observation that approximately 10(6) cells are shed daily per g of tumor. More importantly, our data offer a possible explanation for the antivascular effects of cytotoxic agents and suggest potential strategies for targeting the tumor vasculature.
Collapse
|
research-article |
25 |
459 |
15
|
Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ (CLINICAL RESEARCH ED.) 1992; 304:87-90. [PMID: 1737146 PMCID: PMC1880997 DOI: 10.1136/bmj.304.6819.87] [Citation(s) in RCA: 428] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
OBJECTIVE To determine the prevalence of symptoms compatible with a clinical diagnosis of irritable bowel syndrome in the general population. DESIGN Validated postal questionnaire sent to 2280 subjects randomly selected in 10 year age bands from the lists of eight general practitioners. The Manning criteria were used to define irritable bowel syndrome. SETTING Urban population in Southampton and mixed urban-rural population in Andover, Hampshire. RESULTS A response of 71% yielded 1620 questionnaires for analysis, of which 412 (25%) reported more than six episodes of abdominal pain in the preceding year, with 350 (22%) reporting symptoms consistent with the diagnosis of irritable bowel syndrome. The male: female ratio was 1:1.38. More subjects with irritable bowel syndrome had constipation and diarrhoea and 35% with the syndrome reported rectal bleeding compared with an overall prevalence of 20%. Other symptoms and conditions including heartburn, dyspepsia, flushing, palpitations, migraine, and urinary symptoms were significantly more common in the group with irritable bowel syndrome. Abdominal pain in childhood was more common in the subjects with irritable bowel syndrome (12%) than without (3%). One third of the group with irritable bowel syndrome had sought medical advice during the study period (male:female ratio 1:1.21); consultation behaviour was influenced by age and the presence of associated symptoms, varied considerably among patients registered with different general practitioners, and was poorly correlated with symptom severity. CONCLUSION Symptoms consistent with a diagnosis of irritable bowel syndrome are present in almost one quarter of the general population and tend to be associated with a number of other complaints and conditions, some of which may reflect smooth muscle dysfunction.
Collapse
|
research-article |
33 |
428 |
16
|
Abbott BP, Abbott R, Abbott TD, Abernathy MR, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allocca A, Altin PA, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux CC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Aufmuth P, Aulbert C, Babak S, Bacon P, Bader MKM, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Barayoga JC, Barclay SE, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Baune C, Bavigadda V, Bazzan M, Bejger M, Bell AS, Berger BK, Bergmann G, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Boer M, Bogaert G, Bogan C, Bohe A, Bond C, Bondu F, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bouffanais Y, Bozzi A, et alAbbott BP, Abbott R, Abbott TD, Abernathy MR, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Adya VB, Affeldt C, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Allen B, Allocca A, Altin PA, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux CC, Areeda JS, Arnaud N, Arun KG, Ascenzi S, Ashton G, Ast M, Aston SM, Astone P, Aufmuth P, Aulbert C, Babak S, Bacon P, Bader MKM, Baker PT, Baldaccini F, Ballardin G, Ballmer SW, Barayoga JC, Barclay SE, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Bartos I, Bassiri R, Basti A, Batch JC, Baune C, Bavigadda V, Bazzan M, Bejger M, Bell AS, Berger BK, Bergmann G, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Bhagwat S, Bhandare R, Bilenko IA, Billingsley G, Birch J, Birney R, Birnholtz O, Biscans S, Bisht A, Bitossi M, Biwer C, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bloemen S, Bock O, Boer M, Bogaert G, Bogan C, Bohe A, Bond C, Bondu F, Bonnand R, Boom BA, Bork R, Boschi V, Bose S, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brau JE, Briant T, Brillet A, Brinkmann M, Brisson V, Brockill P, Broida JE, Brooks AF, Brown DA, Brown DD, Brown NM, Brunett S, Buchanan CC, Buikema A, Bulik T, Bulten HJ, Buonanno A, Buskulic D, Buy C, Byer RL, Cabero M, Cadonati L, Cagnoli G, Cahillane C, Calderón Bustillo J, Callister T, Calloni E, Camp JB, Cannon KC, Cao J, Capano CD, Capocasa E, Carbognani F, Caride S, Casanueva Diaz J, Casentini C, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cepeda CB, Cerboni Baiardi L, Cerretani G, Cesarini E, Chamberlin SJ, Chan M, Chao S, Charlton P, Chassande-Mottin E, Cheeseboro BD, Chen HY, Chen Y, Cheng C, Chincarini A, Chiummo A, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua S, Chung S, Ciani G, Clara F, Clark JA, Cleva F, Coccia E, Cohadon PF, Colla A, Collette CG, Cominsky L, Constancio M, Conte A, Conti L, Cook D, Corbitt TR, Cornish N, Corsi A, Cortese S, Costa CA, Coughlin MW, Coughlin SB, Coulon JP, Countryman ST, Couvares P, Cowan EE, Coward DM, Cowart MJ, Coyne DC, Coyne R, Craig K, Creighton JDE, Cripe J, Crowder SG, Cumming A, Cunningham L, Cuoco E, Dal Canton T, Danilishin SL, D'Antonio S, Danzmann K, Darman NS, Dasgupta A, Da Silva Costa CF, Dattilo V, Dave I, Davier M, Davies GS, Daw EJ, Day R, De S, DeBra D, Debreczeni G, Degallaix J, De Laurentis M, Deléglise S, Del Pozzo W, Denker T, Dent T, Dergachev V, De Rosa R, DeRosa RT, DeSalvo R, Devine RC, Dhurandhar S, Díaz MC, Di Fiore L, Di Giovanni M, Di Girolamo T, Di Lieto A, Di Pace S, Di Palma I, Di Virgilio A, Dolique V, Donovan F, Dooley KL, Doravari S, Douglas R, Downes TP, Drago M, Drever RWP, Driggers JC, Ducrot M, Dwyer SE, Edo TB, Edwards MC, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Engels W, Essick RC, Etzel T, Evans M, Evans TM, Everett R, Factourovich M, Fafone V, Fair H, Fairhurst S, Fan X, Fang Q, Farinon S, Farr B, Farr WM, Favata M, Fays M, Fehrmann H, Fejer MM, Fenyvesi E, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Fiori I, Fiorucci D, Fisher RP, Flaminio R, Fletcher M, Fong H, Fournier JD, Frasca S, Frasconi F, Frei Z, Freise A, Frey R, Frey V, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gabbard HAG, Gair JR, Gammaitoni L, Gaonkar SG, Garufi F, Gaur G, Gehrels N, Gemme G, Geng P, Genin E, Gennai A, George J, Gergely L, Germain V, Ghosh A, Ghosh A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill K, Glaefke A, Goetz E, Goetz R, Gondan L, González G, Gonzalez Castro JM, Gopakumar A, Gordon NA, Gorodetsky ML, Gossan SE, Gosselin M, Gouaty R, Grado A, Graef C, Graff PB, Granata M, Grant A, Gras S, Gray C, Greco G, Green AC, Groot P, Grote H, Grunewald S, Guidi GM, Guo X, Gupta A, Gupta MK, Gushwa KE, Gustafson EK, Gustafson R, Hacker JJ, Hall BR, Hall ED, Hamilton H, Hammond G, Haney M, Hanke MM, Hanks J, Hanna C, Hannam MD, Hanson J, Hardwick T, Harms J, Harry GM, Harry IW, Hart MJ, Hartman MT, Haster CJ, Haughian K, Healy J, Heidmann A, Heintze MC, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Hennig J, Henry J, Heptonstall AW, Heurs M, Hild S, Hoak D, Hofman D, Holt K, Holz DE, Hopkins P, Hough J, Houston EA, Howell EJ, Hu YM, Huang S, Huerta EA, Huet D, Hughey B, Husa S, Huttner SH, Huynh-Dinh T, Indik N, Ingram DR, Inta R, Isa HN, Isac JM, Isi M, Isogai T, Iyer BR, Izumi K, Jacqmin T, Jang H, Jani K, Jaranowski P, Jawahar S, Jian L, Jiménez-Forteza F, Johnson WW, Johnson-McDaniel NK, Jones DI, Jones R, Jonker RJG, Ju L, K H, Kalaghatgi CV, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Kapadia SJ, Karki S, Karvinen KS, Kasprzack M, Katsavounidis E, Katzman W, Kaufer S, Kaur T, Kawabe K, Kéfélian F, Kehl MS, Keitel D, Kelley DB, Kells W, Kennedy R, Key JS, Khalili FY, Khan I, Khan S, Khan Z, Khazanov EA, Kijbunchoo N, Kim CW, Kim C, Kim J, Kim K, Kim N, Kim W, Kim YM, Kimbrell SJ, King EJ, King PJ, Kissel JS, Klein B, Kleybolte L, Klimenko S, Koehlenbeck SM, Koley S, Kondrashov V, Kontos A, Korobko M, Korth WZ, Kowalska I, Kozak DB, Kringel V, Krishnan B, Królak A, Krueger C, Kuehn G, Kumar P, Kumar R, Kuo L, Kutynia A, Lackey BD, Landry M, Lange J, Lantz B, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lebigot EO, Lee CH, Lee HK, Lee HM, Lee K, Lenon A, Leonardi M, Leong JR, Leroy N, Letendre N, Levin Y, Lewis JB, Li TGF, Libson A, Littenberg TB, Lockerbie NA, Lombardi AL, London LT, Lord JE, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough JD, Lousto CO, Lück H, Lundgren AP, Lynch R, Ma Y, Machenschalk B, MacInnis M, Macleod DM, Magaña-Sandoval F, Magaña Zertuche L, Magee RM, Majorana E, Maksimovic I, Malvezzi V, Man N, Mandel I, Mandic V, Mangano V, Mansell GL, Manske M, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan AS, Maros E, Martelli F, Martellini L, Martin IW, Martynov DV, Marx JN, Mason K, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matichard F, Matone L, Mavalvala N, Mazumder N, McCarthy R, McClelland DE, McCormick S, McGuire SC, McIntyre G, McIver J, McManus DJ, McRae T, McWilliams ST, Meacher D, Meadors GD, Meidam J, Melatos A, Mendell G, Mercer RA, Merilh EL, Merzougui M, Meshkov S, Messenger C, Messick C, Metzdorff R, Meyers PM, Mezzani F, Miao H, Michel C, Middleton H, Mikhailov EE, Milano L, Miller AL, Miller A, Miller BB, Miller J, Millhouse M, Minenkov Y, Ming J, Mirshekari S, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moggi A, Mohan M, Mohapatra SRP, Montani M, Moore BC, Moore CJ, Moraru D, Moreno G, Morriss SR, Mossavi K, Mours B, Mow-Lowry CM, Mueller G, Muir AW, Mukherjee A, Mukherjee D, Mukherjee S, Mukund N, Mullavey A, Munch J, Murphy DJ, Murray PG, Mytidis A, Nardecchia I, Naticchioni L, Nayak RK, Nedkova K, Nelemans G, Nelson TJN, Neri M, Neunzert A, Newton G, Nguyen TT, Nielsen AB, Nissanke S, Nitz A, Nocera F, Nolting D, Normandin MEN, Nuttall LK, Oberling J, Ochsner E, O'Dell J, Oelker E, Ogin GH, Oh JJ, Oh SH, Ohme F, Oliver M, Oppermann P, Oram RJ, O'Reilly B, O'Shaughnessy R, Ottaway DJ, Overmier H, Owen BJ, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pal-Singh A, Pan H, Pankow C, Pannarale F, Pant BC, Paoletti F, Paoli A, Papa MA, Paris HR, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patricelli B, Patrick Z, Pearlstone BL, Pedraza M, Pedurand R, Pekowsky L, Pele A, Penn S, Perreca A, Perri LM, Pfeiffer HP, Phelps M, Piccinni OJ, Pichot M, Piergiovanni F, Pierro V, Pillant G, Pinard L, Pinto IM, Pitkin M, Poe M, Poggiani R, Popolizio P, Post A, Powell J, Prasad J, Predoi V, Prestegard T, Price LR, Prijatelj M, Principe M, Privitera S, Prix R, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Pürrer M, Qi H, Qin J, Qiu S, Quetschke V, Quintero EA, Quitzow-James R, Raab FJ, Rabeling DS, Radkins H, Raffai P, Raja S, Rajan C, Rakhmanov M, Rapagnani P, Raymond V, Razzano M, Re V, Read J, Reed CM, Regimbau T, Rei L, Reid S, Reitze DH, Rew H, Reyes SD, Ricci F, Riles K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rolland L, Rollins JG, Roma VJ, Romano JD, Romano R, Romanov G, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Sachdev S, Sadecki T, Sadeghian L, Sakellariadou M, Salconi L, Saleem M, Salemi F, Samajdar A, Sammut L, Sanchez EJ, Sandberg V, Sandeen B, Sanders JR, Sassolas B, Sathyaprakash BS, Saulson PR, Sauter OES, Savage RL, Sawadsky A, Schale P, Schilling R, Schmidt J, Schmidt P, Schnabel R, Schofield RMS, Schönbeck A, Schreiber E, Schuette D, Schutz BF, Scott J, Scott SM, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Setyawati Y, Shaddock DA, Shaffer T, Shahriar MS, Shaltev M, Shapiro B, Shawhan P, Sheperd A, Shoemaker DH, Shoemaker DM, Siellez K, Siemens X, Sieniawska M, Sigg D, Silva AD, Singer A, Singer LP, Singh A, Singh R, Singhal A, Sintes AM, Slagmolen BJJ, Smith JR, Smith ND, Smith RJE, Son EJ, Sorazu B, Sorrentino F, Souradeep T, Srivastava AK, Staley A, Steinke M, Steinlechner J, Steinlechner S, Steinmeyer D, Stephens BC, Stevenson SP, Stone R, Strain KA, Straniero N, Stratta G, Strauss NA, Strigin S, Sturani R, Stuver AL, Summerscales TZ, Sun L, Sunil S, Sutton PJ, Swinkels BL, Szczepańczyk MJ, Tacca M, Talukder D, Tanner DB, Tápai M, Tarabrin SP, Taracchini A, Taylor R, Theeg T, Thirugnanasambandam MP, Thomas EG, Thomas M, Thomas P, Thorne KA, Thrane E, Tiwari S, Tiwari V, Tokmakov KV, Toland K, Tomlinson C, Tonelli M, Tornasi Z, Torres CV, Torrie CI, Töyrä D, Travasso F, Traylor G, Trifirò D, Tringali MC, Trozzo L, Tse M, Turconi M, Tuyenbayev D, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, van Veggel AA, Vardaro M, Vass S, Vasúth M, Vaulin R, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Verkindt D, Vetrano F, Viceré A, Vinciguerra S, Vine DJ, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Voss DV, Vousden WD, Vyatchanin SP, Wade AR, Wade LE, Wade M, Walker M, Wallace L, Walsh S, Wang G, Wang H, Wang M, Wang X, Wang Y, Ward RL, Warner J, Was M, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Wen L, Weßels P, Westphal T, Wette K, Whelan JT, Whiting BF, Williams RD, Williamson AR, Willis JL, Willke B, Wimmer MH, Winkler W, Wipf CC, Wittel H, Woan G, Woehler J, Worden J, Wright JL, Wu DS, Wu G, Yablon J, Yam W, Yamamoto H, Yancey CC, Yu H, Yvert M, Zadrożny A, Zangrando L, Zanolin M, Zendri JP, Zevin M, Zhang L, Zhang M, Zhang Y, Zhao C, Zhou M, Zhou Z, Zhu XJ, Zucker ME, Zuraw SE, Zweizig J, Boyle M, Hemberger D, Kidder LE, Lovelace G, Ossokine S, Scheel M, Szilagyi B, Teukolsky S. GW151226: Observation of Gravitational Waves from a 22-Solar-Mass Binary Black Hole Coalescence. PHYSICAL REVIEW LETTERS 2016; 116:241103. [PMID: 27367379 DOI: 10.1103/physrevlett.116.241103] [Show More Authors] [Citation(s) in RCA: 397] [Impact Index Per Article: 44.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Indexed: 05/21/2023]
Abstract
We report the observation of a gravitational-wave signal produced by the coalescence of two stellar-mass black holes. The signal, GW151226, was observed by the twin detectors of the Laser Interferometer Gravitational-Wave Observatory (LIGO) on December 26, 2015 at 03:38:53 UTC. The signal was initially identified within 70 s by an online matched-filter search targeting binary coalescences. Subsequent off-line analyses recovered GW151226 with a network signal-to-noise ratio of 13 and a significance greater than 5σ. The signal persisted in the LIGO frequency band for approximately 1 s, increasing in frequency and amplitude over about 55 cycles from 35 to 450 Hz, and reached a peak gravitational strain of 3.4_{-0.9}^{+0.7}×10^{-22}. The inferred source-frame initial black hole masses are 14.2_{-3.7}^{+8.3}M_{⊙} and 7.5_{-2.3}^{+2.3}M_{⊙}, and the final black hole mass is 20.8_{-1.7}^{+6.1}M_{⊙}. We find that at least one of the component black holes has spin greater than 0.2. This source is located at a luminosity distance of 440_{-190}^{+180} Mpc corresponding to a redshift of 0.09_{-0.04}^{+0.03}. All uncertainties define a 90% credible interval. This second gravitational-wave observation provides improved constraints on stellar populations and on deviations from general relativity.
Collapse
|
|
9 |
397 |
17
|
Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346:732-6. [PMID: 7658874 DOI: 10.1016/s0140-6736(95)91504-4] [Citation(s) in RCA: 392] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Heart failure is commonly associated with high plasma concentrations of endothelin-1, a powerful vasoconstrictor produced by endothelium. The role of endogenously released endothelin-1 in the maintenance of vascular tone in chronic heart failure was assessed by acute administration of an endothelin receptor antagonist, bosentan. 24 patients with chronic heart failure received randomly and double blind two intravenous infusions of either placebo or bosentan (100 mg followed after 60 min by 200 mg). Systemic haemodynamics and plasma endothelin-1 and big-endothelin-1 concentrations were determined before and repeatedly during the 120 min observation period. Baseline endothelin-1 and big-endothelin-1 concentrations, which were above the normal range in all patients, correlated directly with the extent of pulmonary hypertension, with left and right heart filling pressures, and with pulmonary vascular resistance and inversely with cardiac index. Compared with placebo, bosentan reduced mean arterial pressure by 7.7% (95% CI 7.1-9.7), pulmonary artery pressure by 13.7% (10.5-16.9), right atrial pressure by 18.2% (12.0-24.4), and pulmonary artery wedged pressure by 8.6% (5.3-12.0); it increased cardiac index by 13.6% (9.1-18.2), decreased systemic vascular resistance by 16.5% (13.2-19.8), and decreased pulmonary vascular resistance by 33.2% (22.4-44.0). Heart rate did not change. Plasma endothelin-1 concentrations rose more than twofold from baseline in bosentan recipients while big-endothelin-1 concentrations were unchanged. These findings indicate that, in patients with chronic heart failure who have high circulatory endothelin-1 concentrations, this peptide contributes to maintenance of vascular tone. The acute haemodynamic effects of bosentan suggest that chronic endothelin antagonism could be beneficial in such patients.
Collapse
|
Clinical Trial |
30 |
392 |
18
|
Richmond S, Shaw WC, O'Brien KD, Buchanan IB, Jones R, Stephens CD, Roberts CT, Andrews M. The development of the PAR Index (Peer Assessment Rating): reliability and validity. Eur J Orthod 1992; 14:125-39. [PMID: 1582457 DOI: 10.1093/ejo/14.2.125] [Citation(s) in RCA: 379] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The PAR Index has been developed to provide a single summary score for all the occlusal anomalies which may be found in a malocclusion. The score provides an estimate of how far a case deviates from normal alignment and occlusion. The difference in scores between the pre- and post-treatment cases reflects the degree of improvement and, therefore, the success of treatment. Excellent reliability was exhibited within and between examiners (Intraclass Correlation Coefficient, R greater than 0.91). The components of the PAR Index have been weighted to reflect current British orthodontic opinion and is flexible in that the weightings could be changed to reflect future standards and standards currently being achieved in other countries. The PAR Index offers uniformity and standardization in assessing the outcome of orthodontic treatment.
Collapse
|
|
33 |
379 |
19
|
Roberts RG, Flannery TF, Ayliffe LK, Yoshida H, Olley JM, Prideaux GJ, Laslett GM, Baynes A, Smith MA, Jones R, Smith BL. New ages for the last Australian megafauna: continent-wide extinction about 46,000 years ago. Science 2001; 292:1888-92. [PMID: 11397939 DOI: 10.1126/science.1060264] [Citation(s) in RCA: 376] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
All Australian land mammals, reptiles, and birds weighing more than 100 kilograms, and six of the seven genera with a body mass of 45 to 100 kilograms, perished in the late Quaternary. The timing and causes of these extinctions remain uncertain. We report burial ages for megafauna from 28 sites and infer extinction across the continent around 46,400 years ago (95% confidence interval, 51,200 to 39,800 years ago). Our results rule out extreme aridity at the Last Glacial Maximum as the cause of extinction, but not other climatic impacts; a "blitzkrieg" model of human-induced extinction; or an extended period of anthropogenic ecosystem disruption.
Collapse
|
Comment |
24 |
376 |
20
|
Anderson SW, Damasio H, Jones RD, Tranel D. Wisconsin Card Sorting Test performance as a measure of frontal lobe damage. J Clin Exp Neuropsychol 1991; 13:909-22. [PMID: 1779030 DOI: 10.1080/01688639108405107] [Citation(s) in RCA: 373] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We examined the sensitivity and specificity of the Wisconsin Card Sorting Test (WCST) as a measure of frontal lobe damage in 91 subjects with stable focal brain lesions. Anatomical information about the location and extent of brain damage was obtained from MR and CT transparencies. No significant differences in WCST performance were found between subjects with frontal vs. nonfrontal damage. Some subjects with extensive frontal lobe damage performed well on the WCST, and some subjects with damage outside of the frontal lobes failed. The optimal cutoff scores for discriminating frontal from nonfrontal subjects correctly classified only 62% of the subjects. Further analysis of WCST performances associated with damage to various subregions of the frontal lobes also failed to reveal any reliable relationships. These findings indicate that performance on the WCST cannot be interpreted in isolation as an index of frontal lobe damage.
Collapse
|
|
34 |
373 |
21
|
Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS. Selection of the T cell repertoire. Annu Rev Immunol 1999; 17:829-74. [PMID: 10358775 DOI: 10.1146/annurev.immunol.17.1.829] [Citation(s) in RCA: 359] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Advances in gene technology have allowed the manipulation of molecular interactions that shape the T cell repertoire. Although recognized as fundamental aspects of T lymphocyte development, only recently have the mechanisms governing positive and negative selection been examined at a molecular level. Positive selection refers to the active process of rescuing MHC-restricted thymocytes from programmed cell death. Negative selection refers to the deletion or inactivation of potentially autoreactive thymocytes. This review focuses on interactions during thymocyte maturation that define the T cell repertoire, with an emphasis placed on current literature within this field.
Collapse
|
Review |
26 |
359 |
22
|
Fairburn CG, Jones R, Peveler RC, Carr SJ, Solomon RA, O'Connor ME, Burton J, Hope RA. Three psychological treatments for bulimia nervosa. A comparative trial. ARCHIVES OF GENERAL PSYCHIATRY 1991; 48:463-9. [PMID: 2021299 DOI: 10.1001/archpsyc.1991.01810290075014] [Citation(s) in RCA: 349] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The specificity and magnitude of the effects of cognitive behavior therapy in the treatment of bulimia nervosa were evaluated. Seventy-five patients who met strict diagnostic criteria were treated with either cognitive behavior therapy, a simplified behavioral version of this treatment, or interpersonal psychotherapy. Assessment was by interview and self-report questionnaire, and many aspects of functioning were evaluated. All three treatments resulted in an improvement in the measures of the psychopathology. Cognitive behavior therapy was more effective than interpersonal psychotherapy in modifying the disturbed attitudes to shape and weight, extreme attempts to diet, and self-induced vomiting. Cognitive behavior therapy was more effective than behavior therapy in modifying the disturbed attitudes to shape and weight and extreme dieting, but it was equivalent in other respects. The findings suggest that cognitive behavior therapy, when applied to patients with bulimia nervosa, operates through mechanisms specific to this treatment and is more effective than both interpersonal psychotherapy and a simplified behavioral version of cognitive behavior therapy.
Collapse
|
Clinical Trial |
34 |
349 |
23
|
Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11:1132-43. [PMID: 8501500 DOI: 10.1200/jco.1993.11.6.1132] [Citation(s) in RCA: 339] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
PURPOSE We studied high-dose cyclophosphamide, cisplatin, and carmustine (CPA/cDDP/BCNU) with autologous bone marrow support (ABMS) as consolidation after standard-dose adjuvant chemotherapy treatment of primary breast cancer involving 10 or more axillary lymph nodes. PATIENTS AND METHODS One hundred two women with stage IIA, IIB, IIIA, or IIIB breast cancer involving 10 or more lymph nodes at surgery were registered; 85 were eligible, treated, and assessable. Patients were treated with four cycles of standard-dose cyclophosphamide, doxorubicin, and fluorouracil (CAF), followed by high-dose CPA/cDDP/BCNU with ABMS. RESULTS Actuarial event-free survival for the study patients at a median follow-up of 2.5 years is 72% (95% confidence interval, 56% to 82%). Comparison to three historical or concurrent Cancer and Leukemia Group B (CALGB) adjuvant chemotherapy trials selected for similar patients showed event-free survival at 2.5 years to be between 38% and 52%. Therapy-related mortality was 12%; pulmonary toxicity of variable severity occurred in 31% of patients. Quality-of-life evaluations indicate that patients are functioning well without major impairments. CONCLUSION High-dose consolidation with CPA/cDDP/BCNU and ABMS after standard-dose CAF results in a decreased frequency of relapse in patients with high-risk primary breast cancer compared with historical series at the median follow-up of 2.5 years. Evaluation in a prospective, randomized trial is warranted and currently underway.
Collapse
|
Clinical Trial |
32 |
339 |
24
|
Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, Fendrick AM, Jones R, Dent J, Bytzer P. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96:52-7. [PMID: 11197287 DOI: 10.1111/j.1572-0241.2001.03451.x] [Citation(s) in RCA: 323] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVES Brief, reliable, and valid self-administered questionnaires could facilitate the diagnosis of gastroesophageal reflux disease in primary care. We report the development and validation of such an instrument. METHODS Content validity was informed by literature review, expert opinion, and cognitive interviewing of 50 patients resulting in a 22-item survey. For psychometric analyses, primary care patients completed the new questionnaire at enrollment and at intervals ranging from 3 days to 3 wk. Multitrait scaling, test-retest reliability, and responsiveness were assessed. Predictive validity analyses of all scales and items used specialty physician diagnosis as the "gold standard." RESULTS Iterative factor analyses yielded three scales of four items each including heartburn, acid regurgitation, and dyspepsia. Multitrait scaling criteria including internal consistency, item interval consistency, and item discrimination were 100% satisfied. Test-retest reliability was high in those reporting stable symptoms. Scale scores significantly changed in those reporting a global change. Regressing specialty physician diagnosis on the three scales revealed significant effects for two scales (heartburn and regurgitation). Combining the two significant scales enhanced the strength of the model. Symptom response to self-directed treatment with nonprescription antisecretory medications was highly predictive of the diagnosis also, although the item demonstrated poor validity and reliability. CONCLUSIONS A brief, simple 12-item questionnaire demonstrated validity and reliability and seemed to be responsive to change for reflux and dyspeptic symptoms.
Collapse
|
Validation Study |
24 |
323 |
25
|
Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16:147-58. [PMID: 23906415 DOI: 10.1111/dom.12188] [Citation(s) in RCA: 305] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Revised: 05/24/2013] [Accepted: 07/29/2013] [Indexed: 01/06/2023]
Abstract
AIMS This study investigated the efficacy and tolerability of empagliflozin as add-on to pioglitazone ± metformin in patients with type 2 diabetes (T2DM). METHODS Patients with HbA1c ≥7 and ≤10% were randomized and treated with once daily empagliflozin 10 mg (n = 165), empagliflozin 25 mg (n = 168) or placebo (n = 165) as add-on to pioglitazone ± metformin for 24 weeks. Endpoints included changes from baseline in HbA1c (primary endpoint), fasting plasma glucose (FPG) and body weight at week 24. RESULTS Adjusted mean ± standard error changes in HbA1c were -0.6 ± 0.07% and -0.7 ± 0.07% with empagliflozin 10 mg and 25 mg, respectively, vs. -0.1 ± 0.07% with placebo (both p < 0.001). More patients with HbA1c ≥7% at baseline achieved HbA1c <7% with empagliflozin 10 mg (23.8%) and 25 mg (30.0%) vs. placebo (7.7%) (both p < 0.001). FPG decreased with empagliflozin (-0.94 mmol/l for 10 mg and -1.22 mmol/l for 25 mg) and increased with placebo (+0.36 mmol/l; both p < 0.001). Adjusted mean ± standard error changes in weight were -1.62 ± 0.21 kg and -1.47 ± 0.21 kg with empagliflozin 10 mg and 25 mg, respectively, vs. +0.34 ± 0.21 kg with placebo (both p < 0.001). Similar proportions of patients reported adverse events with empagliflozin (67.3-71.4%) and placebo (72.7%). Confirmed hypoglycaemia was reported by 1.2-2.4% of patients on empagliflozin and 1.8% on placebo. CONCLUSION Empagliflozin 10 mg and 25 mg once daily for 24 weeks as add-on to pioglitazone ± metformin reduced HbA1c, FPG and weight and were well tolerated in patients with T2DM.
Collapse
|
Clinical Trial, Phase III |
11 |
305 |